Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
PhenoMiner Database Result        View data table  |  Download data table  |  View compact data table        


Generate Chart For    
    (Chart displayed below)
Rat Strains

{{sample.term}}
Measurement Methods

{{method.term}}
Age

{{ageRange}}
Experimental Conditions

     {{ cond }}

Minimum Value:    Maximum Value:    Sex:


 
Options:  View chart  |  Download data table  |  View compact data table
Study IDStudyExperiment NameExperiment NotesStrain Ont IDStrainSexAge# of AnimalsSample NotesClinical Measurement Ont IDPhenotypeFormulaClinical Measurement NotesAverage TypeValueUnitsSEMSDMethod Ont IDMethodMethod SiteMethod DurationMethod NotesPost Insult TypePost Insult Time ValuePost Insult Time UnitConditionsRecord IDCondition 1Condition 2Condition 3aCondition 3b
268Inomata H, et al., Hypertens Res 2005 Mar;28(3):273-81.body massRS:0000742WKYfemale360 days4CMO:0000012body weight200.8g3.456.9MMO:0000016body weighing method0controlled sodium content diet (0.4 %) (for 122 days) then controlled sodium content diet (1.4 %) (for 210 days)12589controlled sodium content diet (0.4 %) (for 122 days)controlled sodium content diet (1.4 %) (for 210 days)
268Inomata H, et al., Hypertens Res 2005 Mar;28(3):273-81.body massRS:0000742WKYmale360 days4CMO:0000012body weight318g6.6513.3MMO:0000016body weighing method0controlled sodium content diet (0.4 %) (for 122 days) then controlled sodium content diet (1.4 %) (for 210 days)12588controlled sodium content diet (0.4 %) (for 122 days)controlled sodium content diet (1.4 %) (for 210 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.body massRS:0000742WKYmale0 days16CMO:0000012body weight261g7.028.0MMO:0000016body weighing method0.0unx150daysunilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 136 days)107448unilateral nephrectomy (for 150 days)streptozotocin (35 mg/kg) enalapril (10 mg/kg/d) (for 136 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.body massRS:0000742WKYmale0 days16CMO:0000012body weight267g9.036.0MMO:0000016body weighing method0.0unx150daysunilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 136 days) and bosentan (100 mg/kg/d) (for 136 days)107449unilateral nephrectomy (for 150 days)streptozotocin (35 mg/kg) enalapril (10 mg/kg/d) (for 136 days)bosentan (100 mg/kg/d) (for 136 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.body massRS:0000742WKYmale0 days11CMO:0000012body weight408g10.033.1662MMO:0000016body weighing method0.0unx150daysunilateral nephrectomy (for 150 days) then vehicle control condition107445unilateral nephrectomy (for 150 days)vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.body massRS:0000742WKYmale0 days17CMO:0000012body weight274g6.024.7386MMO:0000016body weighing method0.0unx150daysunilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 136 days)107447unilateral nephrectomy (for 150 days)streptozotocin (35 mg/kg) bosentan (100 mg/kg/d) (for 136 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.body massRS:0000742WKYmale0 days17CMO:0000012body weight256g5.020.6155MMO:0000016body weighing method0.0unx150daysunilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then vehicle control condition107446unilateral nephrectomy (for 150 days)streptozotocin (35 mg/kg) vehicle control condition
2826Cerutti C, et al., Physiol Genomics. 2006 Nov 27;27(3):295-308. doi: 10.1152/physiolgenomics.00318.2005. Epub 2006 Aug 1.body massRS:0000742WKYmale84 days5CMO:0000012body weight260g7.015.6525MMO:0000016body weighing method0.0naive control condition (for 0 hours)103476naive control condition (for 0 hours)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.body massRS:0000742WKYmale0 days12CMO:0000012body weight312g4.013.8564MMO:0000016body weighing method0.0PA IV 50mg/kgcontrolled enalapril content drinking water (50 mg/l) (between 63 and 77 days) then puromycin aminonucleoside (50 mg/kg) 100396controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days)puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.body massRS:0000742WKYmale0 days12CMO:0000012body weight323g5.017.3205MMO:0000016body weighing method0.0PA IV 50mg/kgpuromycin aminonucleoside (50 mg/kg) 100395puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.body massRS:0000742WKYmale0 days11CMO:0000012body weight319g5.016.5831MMO:0000016body weighing method0.00.9% sodium chloride solution (3 ml) 1003940.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.body massRS:0000742WKYmale0 days10CMO:0000012body weight241g5.015.8114MMO:0000016body weighing method0.00.9% sodium chloride solution (3 ml) 1003910.9% sodium chloride solution (3 ml)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.body massRS:0000742WKYmale0 days6CMO:0000012body weight229g6.014.6969MMO:0000016body weighing method0.0unx28daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 14 days) and bosentan (100 mg/kg/d) (for 14 days)99939unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) enalapril (10 mg/kg/d) (for 14 days)bosentan (100 mg/kg/d) (for 14 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.body massRS:0000742WKYmale0 days8CMO:0000012body weight233g5.014.1421MMO:0000016body weighing method0.0unx28daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 14 days)99938unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) enalapril (10 mg/kg/d) (for 14 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.body massRS:0000742WKYmale0 days8CMO:0000012body weight236g7.019.799MMO:0000016body weighing method0.0unx28daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 14 days)99937unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) bosentan (100 mg/kg/d) (for 14 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.body massRS:0000742WKYmale0 days8CMO:0000012body weight215g10.028.2843MMO:0000016body weighing method0.0unx28daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition99936unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.body massRS:0000742WKYmale0 days7CMO:0000012body weight268g13.034.3948MMO:0000016body weighing method0.0unx28daysunilateral nephrectomy (for 28 days) then vehicle control condition99935unilateral nephrectomy (for 28 days)vehicle control condition
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.body massRS:0000742WKYmale0 days9CMO:0000012body weight395g7.021.0MMO:0000016body weighing method0.0PA IV 50mg/kg490dayscontrolled enalapril content drinking water (50 mg/l) (for 497 days) then puromycin aminonucleoside (50 mg/kg) 100435controlled enalapril content drinking water (50 mg/l) (for 497 days)puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.body massRS:0000742WKYmale0 days8CMO:0000012body weight418g15.042.4264MMO:0000016body weighing method0.0PA IV 50mg/kg490dayspuromycin aminonucleoside (50 mg/kg) 100434puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.body massRS:0000742WKYmale0 days9CMO:0000012body weight412g6.018.0MMO:0000016body weighing method0.00.9% sodium chloride solution (3 ml) 1004330.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.body massRS:0000742WKYmale0 days8CMO:0000012body weight305g6.016.9706MMO:0000016body weighing method0.0PA IV 50mg/kgcontrolled enalapril content drinking water (50 mg/l) (between 63 and 77 days) then puromycin aminonucleoside (50 mg/kg) 100432controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days)puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.body massRS:0000742WKYmale0 days9CMO:0000012body weight297g4.012.0MMO:0000016body weighing method0.0PA IV 50mg/kgpuromycin aminonucleoside (50 mg/kg) 100431puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.body massRS:0000742WKYmale0 days8CMO:0000012body weight317g10.028.2843MMO:0000016body weighing method0.00.9% sodium chloride solution (3 ml) 1004300.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.body massRS:0000742WKYmale0 days5CMO:0000012body weight245g12.026.8328MMO:0000016body weighing method0.0PA IV 50mg/kg15dayscontrolled enalapril content drinking water (50 mg/l) (for 22 days) then puromycin aminonucleoside (50 mg/kg) 100429controlled enalapril content drinking water (50 mg/l) (for 22 days)puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.body massRS:0000742WKYmale0 days7CMO:0000012body weight245g9.023.8118MMO:0000016body weighing method0.0PA IV 50mg/kg15dayspuromycin aminonucleoside (50 mg/kg) 100428puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.body massRS:0000742WKYmale0 days9CMO:0000012body weight244g8.024.0MMO:0000016body weighing method0.00.9% sodium chloride solution (3 ml) 1004270.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.body massRS:0000742WKYmale0 days10CMO:0000012body weight241g5.015.8114MMO:0000016body weighing method0.0PA IV 50mg/kg15dayscontrolled enalapril content drinking water (50 mg/l) (for 22 days) then puromycin aminonucleoside (50 mg/kg) 100393controlled enalapril content drinking water (50 mg/l) (for 22 days)puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.body massRS:0000742WKYmale0 days11CMO:0000012body weight249g11.036.4829MMO:0000016body weighing method0.0PA IV 50mg/kg15dayspuromycin aminonucleoside (50 mg/kg) 100392puromycin aminonucleoside (50 mg/kg)
2219Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.body massRS:0000742WKYmale156 days10CMO:0000012body weight286.6g21.9569.412MMO:0000016body weighing method0.0daysstreptozotocin (60 mg/kg) then benazepril (10 mg/kg/d) then gene transfer of the murine angiotensin I converting enzyme 2 gene using an adenovirus vector (40000000000 null) 99112streptozotocin (60 mg/kg) benazepril (10 mg/kg/d) gene transfer of the murine angiotensin I converting enzyme 2 gene using an adenovirus vector (40000000000 null)
2219Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.body massRS:0000742WKYmale156 days10CMO:0000012body weight287.24g20.1863.8148MMO:0000016body weighing method0.0daysstreptozotocin (60 mg/kg) then benazepril (10 mg/kg/d) 99111streptozotocin (60 mg/kg) benazepril (10 mg/kg/d)
2219Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.body massRS:0000742WKYmale156 days10CMO:0000012body weight295.56g21.8969.2223MMO:0000016body weighing method0.0daysstreptozotocin (60 mg/kg) then gene transfer of the murine angiotensin I converting enzyme 2 gene using an adenovirus vector (40000000000 null) 99110streptozotocin (60 mg/kg) gene transfer of the murine angiotensin I converting enzyme 2 gene using an adenovirus vector (40000000000 null)
2219Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.body massRS:0000742WKYmale156 days10CMO:0000012body weight261.43g21.3467.483MMO:0000016body weighing method0.0daysstreptozotocin (60 mg/kg) then gene transfer of the enhanced green fluorescent protein gene using an adenovirus vector (40000000000 null) 99109streptozotocin (60 mg/kg) gene transfer of the enhanced green fluorescent protein gene using an adenovirus vector (40000000000 null)
2219Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.body massRS:0000742WKYmale156 days10CMO:0000012body weight259.65g18.9659.9568MMO:0000016body weighing method0.0daysstreptozotocin (60 mg/kg) 99108streptozotocin (60 mg/kg)
2219Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.body massRS:0000742WKYmale156 days10CMO:0000012body weight450.39g9.3629.5989MMO:0000016body weighing method0.0daysvehicle control condition (1 null) 99107vehicle control condition (1 null)
2338Ohashi H, et al., Jpn Circ J. 1986 Feb;50(2):140-6.body massRS:0000742WKYmale245 days7CMO:0000012body weight373.6g11.112229.4MMO:0000016body weighing method0.0naive control condition99849naive control condition
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.body massRS:0000742WKYmale280 days to 266 days32CMO:0000012body weight574g38.0214.9605MMO:0000016body weighing method0.0lad occlusion210daysleft anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ramipril (1 mg/kg/d) (for 182 days)100275left anterior descending coronary artery occlusion (for 224 days)furosemide (10 mg/kg/d) (for 161 days)ramipril (1 mg/kg/d) (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.body massRS:0000742WKYmale280 days to 266 days16CMO:0000012body weight599g35.0140.0MMO:0000016body weighing method0.0lad occlusion210daysleft anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days)100274left anterior descending coronary artery occlusion (for 224 days)furosemide (10 mg/kg/d) (for 161 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.body massRS:0000742WKYmale280 days to 266 days5CMO:0000012body weight562g22.049.1935MMO:0000016body weighing method0.0lad occlusion sham210dayssham surgical control condition (for 224 days)100273sham surgical control condition (for 224 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.body massRS:0000742WKYmale252 days to 238 days30CMO:0000012body weight617g52.0284.8157MMO:0000016body weighing method0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days)100272left anterior descending coronary artery occlusion (for 196 days)vehicle control condition (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.body massRS:0000742WKYmale252 days to 238 days20CMO:0000012body weight583g56.0250.4396MMO:0000016body weighing method0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days)100271left anterior descending coronary artery occlusion (for 196 days)furosemide (10 ml/kg/d) (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.body massRS:0000742WKYmale252 days to 238 days12CMO:0000012body weight566g17.058.8897MMO:0000016body weighing method0.0lad occlusion sham196dayssham surgical control condition (for 196 days)100270sham surgical control condition (for 196 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.body massRS:0000742WKYmale56 days to 42 days30CMO:0000012body weight225g1.89.859MMO:0000016body weighing method0.0lad occlusion0daysleft anterior descending coronary artery occlusion then vehicle control condition100269left anterior descending coronary artery occlusionvehicle control condition
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.body massRS:0000742WKYmale56 days to 42 days20CMO:0000012body weight225g3.013.4164MMO:0000016body weighing method0.0lad occlusion0daysleft anterior descending coronary artery occlusion then furosemide100268left anterior descending coronary artery occlusionfurosemide
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.body massRS:0000742WKYmale56 days to 42 days12CMO:0000012body weight223g1.44.8497MMO:0000016body weighing method0.0lad occlusion0dayssham surgical control condition100267sham surgical control condition
2218Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.body massRS:0000742WKYmale112 days18CMO:0000012body weight436g11.046.669MMO:0000016body weighing method0.0in utero condition (30 % of calories) (for 22 days)99076in utero condition (30 % of calories) (for 22 days)
2218Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.body massRS:0000742WKYmale112 days17CMO:0000012body weight454g8.032.9848MMO:0000016body weighing method0.0controlled in utero environment (100 % of calories) (for 22 days)99075controlled in utero environment (100 % of calories) (for 22 days)
2218Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.body massRS:0000742WKYnot specified1 days36CMO:0000012body weight4.91g0.150.9MMO:0000016body weighing method0.0in utero condition (30 % of calories) (for 22 days)99074in utero condition (30 % of calories) (for 22 days)
2218Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.body massRS:0000742WKYnot specified1 days26CMO:0000012body weight6.64g0.140.7139MMO:0000016body weighing method0.0controlled in utero environment (100 % of calories) (for 22 days)99073controlled in utero environment (100 % of calories) (for 22 days)